Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to post $1.04 billion in sales for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $1.13 billion and the lowest is $1.02 billion. Nektar Therapeutics posted sales of $34.59 million during the same quarter last year, which suggests a positive year-over-year growth rate of 2,906.6%. The business is scheduled to report its next quarterly earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year sales of $1.15 billion for the current financial year, with estimates ranging from $1.10 billion to $1.24 billion. For the next fiscal year, analysts anticipate that the business will report sales of $249.92 million per share, with estimates ranging from $100.20 million to $528.34 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.08). Nektar Therapeutics had a negative return on equity of 202.41% and a negative net margin of 40.07%. The business had revenue of $38.02 million for the quarter, compared to the consensus estimate of $35.59 million. During the same quarter in the previous year, the company earned ($0.42) earnings per share. The firm’s revenue was up 53.7% on a year-over-year basis.
Several research analysts have issued reports on the stock. HC Wainwright set a $125.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Monday, May 14th. BidaskClub cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Mizuho increased their target price on shares of Nektar Therapeutics from $89.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, April 6th. Finally, ValuEngine cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Nektar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $76.42.
In related news, SVP Stephen K. Doberstein sold 160,000 shares of Nektar Therapeutics stock in a transaction that occurred on Monday, April 9th. The shares were sold at an average price of $93.06, for a total value of $14,889,600.00. Following the completion of the sale, the senior vice president now directly owns 127,394 shares in the company, valued at approximately $11,855,285.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Howard W. Robin sold 130,000 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 3rd. The stock was sold at an average price of $84.05, for a total transaction of $10,926,500.00. Following the completion of the sale, the chief executive officer now owns 280,481 shares of the company’s stock, valued at $23,574,428.05. The disclosure for this sale can be found here. Insiders sold a total of 751,609 shares of company stock worth $59,177,957 over the last 90 days. Company insiders own 4.31% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in NKTR. Schroder Investment Management Group boosted its stake in Nektar Therapeutics by 90.9% in the 4th quarter. Schroder Investment Management Group now owns 14,016 shares of the biopharmaceutical company’s stock worth $837,000 after purchasing an additional 6,675 shares in the last quarter. Amalgamated Bank raised its position in Nektar Therapeutics by 6.3% during the 4th quarter. Amalgamated Bank now owns 21,775 shares of the biopharmaceutical company’s stock worth $1,300,000 after buying an additional 1,298 shares during the last quarter. Geode Capital Management LLC raised its position in Nektar Therapeutics by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 1,445,971 shares of the biopharmaceutical company’s stock worth $86,353,000 after buying an additional 13,958 shares during the last quarter. Alliancebernstein L.P. raised its position in Nektar Therapeutics by 14.0% during the 4th quarter. Alliancebernstein L.P. now owns 263,506 shares of the biopharmaceutical company’s stock worth $15,737,000 after buying an additional 32,269 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in Nektar Therapeutics during the 4th quarter worth approximately $11,293,000. Institutional investors own 90.76% of the company’s stock.
Nektar Therapeutics stock traded down $0.02 during midday trading on Friday, hitting $48.83. 3,091,300 shares of the company’s stock were exchanged, compared to its average volume of 3,815,424. The company has a debt-to-equity ratio of 4.21, a current ratio of 4.16 and a quick ratio of 4.03. Nektar Therapeutics has a 12 month low of $17.51 and a 12 month high of $111.36. The stock has a market cap of $8.37 billion, a price-to-earnings ratio of -88.78 and a beta of 1.97.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.